Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 2/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22902068 | 0.83 | NOTUM (0.50) | NOTUMMTOR | |
| SCHEMBL24908424 | 0.82 | GRM5 (0.54) | NOTUMIRAK4CREBBPKCNJ1 | |
| SCHEMBL24908620 | 0.80 | IRAK4 (0.36) | IRAK4PANK3EP300MTOR | |
| SCHEMBL24908618 | 0.80 | KDM4E (0.49) | IRAK4CYP19A1PANK3CYP11B2CYP3A4 | |
| SCHEMBL26051361 | 0.80 | MAPT (0.42) | NOTUMMTOR | |
| SCHEMBL15119356 | 0.78 | KDM5B (0.43) | NOTUMMTOR | |
| SCHEMBL1159675 | 0.78 | ALDH1A1 (0.47) | NOTUMCYP19A1EP300MAPKAPK2CYP11B2 | |
| SCHEMBL12351974 | 0.78 | GAA (0.53) | — | |
| SCHEMBL24908614 | 0.77 | CYP11B1 (0.42) | CYP11B2CYP11B1CACNA1H | |
| SCHEMBL19531652 | 0.76 | MELK (0.42) | NOTUMCREBBPMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | NOTUM 2481/4885IRAK4 439/4885CYP19A1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.